Display options
Cite
Njom Nlend AE, Nguwoh PS, Ngounouh CT, et al. HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings?. PLoS One. 2016;11(9):e0161714doi: 10.1371/journal.pone.0161714.
Njom Nlend, A. E., Nguwoh, P. S., Ngounouh, C. T., Tchidjou, H. K., Pieme, C. A., Otélé, J. M., Penlap, V., Colizzi, V., Moyou, R. S., & Fokam, J. (2016). HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings?. PloS one, 11(9), e0161714. https://doi.org/10.1371/journal.pone.0161714
Njom Nlend, Anne Esther, et al. "HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings?." PloS one vol. 11,9 (2016): e0161714. doi: https://doi.org/10.1371/journal.pone.0161714
Njom Nlend AE, Nguwoh PS, Ngounouh CT, Tchidjou HK, Pieme CA, Otélé JM, Penlap V, Colizzi V, Moyou RS, Fokam J. HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings?. PLoS One. 2016 Sep 22;11(9):e0161714. doi: 10.1371/journal.pone.0161714. eCollection 2016. PMID: 27656883; PMCID: PMC5033457.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2016 Sep 22;11(9):e0161714. doi: 10.1371/journal.pone.0161714. eCollection 2016.

HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings?.

PloS one

Anne Esther Njom Nlend, Philippe Salomon Nguwoh, Christian Taheu Ngounouh, Hyppolite Kuekou Tchidjou, Constant Anatole Pieme, Jean Mbede Otélé, Véronique Penlap, Vittorio Colizzi, Roger Somo Moyou, Joseph Fokam

Affiliations

  1. Pediatric Service, National Insurance Fund Welfare Hospital, Yaoundé, Cameroon.
  2. Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
  3. Higher Institute of Health Professions, Yaoundé, Cameroon.
  4. Ministry of Public Health, Yaoundé, Cameroon.
  5. Institute of Science and Technology Applied to Health, Yaoundé, Cameroon.
  6. Bambino Gesu Paediatric Hospital, Rome, Italy.
  7. Department of Biochemistry and Microbiology, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon.
  8. Chantal BIYA International Reference Centre for Research on HIV/AIDS prevention and management, Yaoundé, Cameroon.
  9. University of Rome Tor Vergata, Rome, Italy.
  10. UNESCO Interdisciplinary Board of Biotechnology, Rome, Italy.
  11. Institute of Research in Medicine and Medicinal plants, Yaoundé, Cameroon.

PMID: 27656883 PMCID: PMC5033457 DOI: 10.1371/journal.pone.0161714

Abstract

BACKGROUND: Since 2005, anti-hepatitis B virus (anti-HBV) vaccine is part of the Expanded Program on Immunization (EPI) for infants born in Cameroon, with 99% anti-HBV coverage. In a context of generalized HIV epidemiology, we assessed paediatric anti-HBV vaccine response according to HIV status, feeding option and age in a tropical context.

METHODOLOGY: Prospective, observational and cross-sectional study conducted among 82 children (27 [IQR: 9-47] months, min-max: 6-59), after complete anti-HBV vaccination (Zilbrix Hepta: 10μg AgHBs) at the Essos Health Centre in Yaounde, Cameroon, classified as group-A: HIV unexposed (28), group-B: HIV-exposed/uninfected (29), group-C: HIV-infected (25). Quantitative anti-HBs ELISA was interpreted as "no", "low-" or "protective-response" with <1, 1-10, or ≥10 IU/L respectively; with p-value<0.05 considered significant.

RESULTS: Children were all HBV-unexposed (AcHBc-negative) and uninfected (HBsAg-negative). Response to anti-HBV vaccine was 80.49% (66/82), with only 45.12% (37/82) developed a protective-response (≥10IU/L). According to HIV status, 60.71% (17/28) developed a protective-response in group-A, vs. 51.72% (15/29) and 20% (5/25) in group-B and group-C respectively, Odds Ratio (OR): 2.627 [CI95% 0.933-7.500], p = 0.041. According to feeding option during first six months of life, 47.67% (21/45) developed a protective-response on exclusive breastfeeding vs. 43.24% (16/37) on mixed or formula feeding, OR: 1.148 [CI95% 0.437-3.026], p = 0.757. According to age, protective-response decreased significantly as children grow older: 58.33% (28/48) <24 months vs. 26.47% (9/34) ≥24 months, OR: 3.889 [CI95% 1.362-11.356], p = 0.004; and specifically 67.65% (23/34) ≤6 months vs. 0%, (0/5) 33-41 months, p = 0.008.

CONCLUSIONS: Anti-HBV vaccine provides low rate of protection (<50%) among children in general, and particularly if HIV-exposed, infected and/or older children. Implementing policies for early vaccination, specific immunization algorithm for HIV-exposed/infected children, and monitoring vaccine response would ensure effective protection in tropical settings, pending extensive/confirmatory investigations.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. J Nutr. 2008 Sep;138(9):1782S-1790S - PubMed
  2. Indian J Pediatr. 2016 Aug;83(8):772-6 - PubMed
  3. Pediatr Infect Dis J. 2013 Oct;32(10):1110-5 - PubMed
  4. Pediatr Res. 2008 Jul;64(1):100-4 - PubMed
  5. AIDS. 1994 Sep;8(9):1281-4 - PubMed
  6. Clin Vaccine Immunol. 2011 Sep;18(9):1406-9 - PubMed
  7. Vaccine. 2016 Jul 12;34(32):3702-9 - PubMed
  8. BMC Infect Dis. 2015 Jul 12;15:267 - PubMed
  9. J Infect Dis. 2013 Apr;207(7):1047-57 - PubMed
  10. Hepatology. 2009 May;49(5 Suppl):S138-45 - PubMed
  11. BMJ. 2006 Feb 11;332(7537):328-36 - PubMed
  12. Curr HIV Res. 2016;14 (2):165-71 - PubMed
  13. Lancet Infect Dis. 2007 Jun;7(6):402-9 - PubMed
  14. Hepatology. 2015 Apr;61(4):1183-91 - PubMed
  15. PLoS One. 2012;7(5):e38153 - PubMed
  16. Wkly Epidemiol Rec. 2008 Nov 28;83(48):429-34 - PubMed
  17. N Engl J Med. 2012 May 10;366(19):1749-52 - PubMed
  18. J Infect Dis. 2016 Jul 1;214(1):16-22 - PubMed
  19. PLoS One. 2016 Jun 09;11(6):e0157161 - PubMed
  20. Vaccine. 2004 Jan 2;22(3-4):511-9 - PubMed
  21. J Infect Dis. 2013 Feb 1;207(3):402-10 - PubMed
  22. Pan Afr Med J. 2015 Jan 29;20:79 - PubMed
  23. Hepatol Res. 2007 Jul;37(s1):S9-S19 - PubMed
  24. J Med Virol. 2017 Jan;89(1):182-185 - PubMed
  25. PLoS One. 2015 Nov 16;10(11):e0143043 - PubMed
  26. Curr HIV Res. 2015;13(4):286-91 - PubMed

Publication Types